KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Common Equity: 2009-2024

Historic Common Equity for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $363.8 million.

  • Halozyme Therapeutics' Common Equity rose 11.31% to $503.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $503.9 million, marking a year-over-year increase of 11.31%. This contributed to the annual value of $363.8 million for FY2024, which is 334.11% up from last year.
  • As of FY2024, Halozyme Therapeutics' Common Equity stood at $363.8 million, which was up 334.11% from $83.8 million recorded in FY2023.
  • Halozyme Therapeutics' Common Equity's 5-year high stood at $363.8 million during FY2024, with a 5-year trough of $83.8 million in FY2023.
  • Moreover, its 3-year median value for Common Equity was $169.8 million (2022), whereas its average is $205.8 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Common Equity tumbled by 50.64% in 2023, and later spiked by 334.11% in 2024.
  • Halozyme Therapeutics' Common Equity (Yearly) stood at $151.0 million in 2020, then surged by 30.39% to $197.0 million in 2021, then declined by 13.79% to $169.8 million in 2022, then slumped by 50.64% to $83.8 million in 2023, then soared by 334.11% to $363.8 million in 2024.